The dawn of a new era: targeting the “undruggables” with antibody-based therapeutics
The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
Novel antimicrobial agents for combating antibiotic-resistant bacteria
Antibiotic therapy has become increasingly ineffective against bacterial infections due to the
rise of resistance. In particular, ESKAPE pathogens (Enterococcus faecium, Staphylococcus …
rise of resistance. In particular, ESKAPE pathogens (Enterococcus faecium, Staphylococcus …
Membranous nephropathy: new pathogenic mechanisms and their clinical implications
E Hoxha, L Reinhard, RAK Stahl - Nature Reviews Nephrology, 2022 - nature.com
Membranous nephropathy (MN) is characterized histomorphologically by the presence of
immune deposits in the subepithelial space of the glomerular filtration barrier; its clinical …
immune deposits in the subepithelial space of the glomerular filtration barrier; its clinical …
Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies
Standard cancer therapies sometimes fail to deliver chemotherapeutic drugs to tumor cells
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …
in a safe and effective manner. Nanotechnology takes the lead in providing new therapeutic …
[HTML][HTML] A review of bispecific antibodies and antibody constructs in oncology and clinical challenges
Bispecific antibodies (bsAbs) are antibodies that bind two distinct epitopes to cancer.. For
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
use in oncology, one bsAb has been approved and 57 bsAbs are in clinical trials, none of …
Targeting cancer with antibody-drug conjugates: Promises and challenges
Antibody-drug conjugates (ADCs) are a rapidly expanding class of biotherapeutics that
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …
utilize antibodies to selectively deliver cytotoxic drugs to the tumor site. As of May 2021, the …
[HTML][HTML] Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-cell sequencing of convalescent patients' B cells
The COVID-19 pandemic urgently needs therapeutic and prophylactic interventions. Here,
we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput …
we report the rapid identification of SARS-CoV-2-neutralizing antibodies by high-throughput …
[HTML][HTML] Phase 3 study of ibalizumab for multidrug-resistant HIV-1
B Emu, J Fessel, S Schrader, P Kumar… - … England Journal of …, 2018 - Mass Medical Soc
Abstract Background Ibalizumab, a humanized IgG4 monoclonal antibody, blocks the entry
of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4. Methods …
of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4. Methods …
Challenges and strategies for developing efficacious and long-lasting malaria vaccines
Although there has been major recent progress in malaria vaccine development, substantial
challenges remain for achieving highly efficacious and durable vaccines against …
challenges remain for achieving highly efficacious and durable vaccines against …
IgG and Fcγ receptors in intestinal immunity and inflammation
T Castro-Dopico, MR Clatworthy - Frontiers in immunology, 2019 - frontiersin.org
Fcγ receptors (FcγR) are cell surface glycoproteins that mediate cellular effector functions of
immunoglobulin G (IgG) antibodies. Genetic variation in FcγR genes can influence …
immunoglobulin G (IgG) antibodies. Genetic variation in FcγR genes can influence …